Overview
Episodic ataxia type 1 (EA1) is an autosomal-dominant neurological disorder characterized by recurrent episodes of ataxia and continuous myokymia, caused by mutations in the KCNA1 gene encoding potassium channels 1.Diagnosis
Clinical features include episodic ataxia and continuous myokymia.
Genetic testing: Sequencing of KCNA1 gene for mutations, including novel deletions 1.
Respiratory symptoms such as paroxysmal dyspnea may be observed, expanding clinical presentation 1.Management
First-line treatment: No specific drug doses mentioned in the abstract; symptomatic management is typically employed.
Adjunctive treatments: Carbamazepine and acetazolamide have been used in some cases, though specific dosing is not detailed here 1.Special Populations
Respiratory involvement: Novel findings suggest potential respiratory muscle involvement requiring careful monitoring in affected individuals 1.Key Recommendations
Genetic testing of KCNA1 should be considered for definitive diagnosis of episodic ataxia type 1 (Evidence: Moderate) 1.
Monitor for atypical symptoms such as paroxysmal dyspnea, expanding the clinical assessment beyond typical ataxic episodes (Evidence: Weak) 1.
Symptomatic treatment approaches should be tailored to individual patient needs, though specific drug recommendations require further evidence (Evidence: Expert opinion) 1.References
1 Shook SJ, Mamsa H, Jen JC, Baloh RW, Zhou L. Novel mutation in KCNA1 causes episodic ataxia with paroxysmal dyspnea. Muscle & nerve 2008. link